- Global Pharma News & Resources

Hypertrophic Cardiomyopathy Pipeline Review, H2 2018 Featuring C&C BioPharma, Lead Discovery Center & MyoKardia -

The "Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018" drug pipelines has been added to's offering.

Hypertrophic Cardiomyopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Hypertrophic Cardiomyopathy - Overview
  4. Hypertrophic Cardiomyopathy - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Pipeline by Universities/Institutes
  8. Products under Development by Companies
  9. Products under Development by Universities/Institutes
  10. Hypertrophic Cardiomyopathy - Therapeutics Assessment
  11. Assessment by Target
  12. Assessment by Mechanism of Action
  13. Assessment by Route of Administration
  14. Assessment by Molecule Type
  15. Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
  • C&C BioPharma LLC
  • Lead Discovery Center GmbH
  • MyoKardia Inc

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018